paclitaxel

Everolimus Eluting Stent in multiple vessels with short SYNTAX score

Original title:&nbsp;A Clinical and Angiographic Study of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With Multivessel Coronary Artery Disease. The EXECUTIVE (EXecutive RCT: Evaluating XIENCE V in a Multi Vessel Disease) Trial.&nbsp;Reference:&nbsp;Flavio Ribichini et al. J Am Coll Cardiol Intv 2013. Article in press. Drug-eluting stents (DES ) have emerged<a href="https://solaci.org/en/2013/09/24/everolimus-eluting-stent-in-multiple-vessels-with-short-syntax-score/" title="Read more" >...</a>

DES versus Bare in primary angioplasty at five years. Initial advantage is reducing

Original: title&nbsp;Long-Term Outcome After Drug-Eluting VersusBare-Metal Stent Implantation in Patients WithST-Segment Elevation Myocardial Infarction. 5 Years Follow-Up From the Randomized DEDICATION (Drug Elution and DistalProtection in Acute Myocardial Infarction) Trial.&nbsp;Reference:&nbsp;Lene Holmvang et al. J Am CollCardiolIntv 2013, article in press. &nbsp; Primary angioplasty reduced mortality and reinfarction compared with thrombolytics in patients experiencing an ST<a href="https://solaci.org/en/2013/07/05/des-versus-bare-in-primary-angioplasty-at-five-years-initial-advantage-is-reducing/" title="Read more" >...</a>

Safety and superior effectiveness over two years in femoropopliteal region with drug-eluting stents

Original title:&nbsp;Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: two-year follow-up from the Zilver PTX randomized and single-arm clinical studies.&nbsp;Reference:&nbsp;Michael D. Dake et al. J Am Coll Cardiol 2013. Article in press. Studies with long-term monitoring showed mainly the limited permeability of balloon angioplasty, especially over challenging injuries such as total occlusions or<a href="https://solaci.org/en/2013/05/13/safety-and-superior-effectiveness-over-two-years-in-femoropopliteal-region-with-drug-eluting-stents/" title="Read more" >...</a>

More evidence for drug eluting balloons in the femoropopliteal region

Original title:&nbsp;2-Year Results of Paclitaxel-Eluting Balloons for Femoropopliteal Artery Disease. Evidence From a Multicenter Registry.&nbsp;Reference:&nbsp;Antonio Micari et al. J Am Coll Cardiol Intv 2013;6:282&ndash;9. Paclitaxel-eluting balloons appear safe and effective for treating atherosclerotic lesions in the femoropopliteal region, leaving the stent only as a rescue strategy against a suboptimal outcome. However, the vast majority of<a href="https://solaci.org/en/2013/04/20/more-evidence-for-drug-eluting-balloons-in-the-femoropopliteal-region/" title="Read more" >...</a>

First results of bioabsorbable metal scaffolds DREAMS

Original title:&nbsp;Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial.&nbsp;Reference:&nbsp;Michael Haude et al. Lancet 2013; 381: 836&ndash;44. Bioabsorbable scaffolds could improve vasomotion, remodelling and facilitate new interventions, both percutaneous and surgical. This new bioabsorbable scaffold, different from the<a href="https://solaci.org/en/2013/04/18/first-results-of-bioabsorbable-metal-scaffolds-dreams/" title="Read more" >...</a>

5 Year Follow Up Outcome of Zotarolimus Eluting Stent

Original title:&nbsp;The &#8220;Final&#8221; 5-Year Follow-Up From the ENDEAVOR IV Trial Comparing a Zotarolimus-Eluting Stent With a Paclitaxel-Eluting Stent. ENDEAVOR IV Investigators&nbsp;Reference:&nbsp;Ajay J. Kirtane et al. J Am Coll Cardiol Intv 2013. Article in press. The ENDEAVOR IV was a randomized controlled study with a noninferiority design that compared the Endeavor zotarolimus eluting stent (Medtronic, Santa<a href="https://solaci.org/en/2013/04/12/5-year-follow-up-outcome-of-zotarolimus-eluting-stent/" title="Read more" >...</a>

The largest series of femoropopliteal in-stent restenosis to date 

Original title:&nbsp;Treatment of Femoropopliteal In-Stent Restenosis With Paclitaxel-Eluting Stents. Zilver PTX Global Registry. ZILVER-PTX.&nbsp;Reference:&nbsp;Thomas Zeller et al. J Am Coll Cardiol Intv 2013;6:274&ndash;81. Femoropopliteal in-stent restenosis (ISR) is reported in between 19% and 37% of lesions a year and this incidence increases with lesion length.&nbsp; The ZILVER-PTX study tested the self-expanding paclitaxel-eluting nitinol stent (Cook<a href="https://solaci.org/en/2013/04/08/the-largest-series-of-femoropopliteal-in-stent-restenosis-to-date/" title="Read more" >...</a>

Rotational atherectomy is only an interim strategy.

Original title:&nbsp;High-Speed Rotational Atherectomy Before Paclitaxel-Eluting Stent Implantation in Complex Calcified Coronary Lesions. The Randomized ROTAXUS (Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease) Trial.&nbsp;Reference:&nbsp;Mohamed Abdel-Wahab et al. J Am Coll Cardiol Intv 2013; article in press Heavily calcified lesions are difficult and may prevent the appropriate expansion of a<a href="https://solaci.org/en/2013/01/04/rotational-atherectomy-is-only-an-interim-strategy/" title="Read more" >...</a>

Future strategies to prevent restenosis and stent thrombosis

Original title:&nbsp;Endothelial cell repopulation after stenting determines in-stent neointima formation: effects of bare-metal vs. drug-eluting stents and genetic endothelial cell modification.&nbsp;Reference:&nbsp;Douglas G et al. European Heart Journal doi:10.1093/eurheartj/ehs240 Experimental models of vascular injury have shown that the rate of endothelial cell repopulation post-injury is a critical factor in determining subsequent neointima formation as well as<a href="https://solaci.org/en/2012/12/04/future-strategies-to-prevent-restenosis-and-stent-thrombosis/" title="Read more" >...</a>

Cilostazol reduces restenosis in infrapopliteal angioplasty

Original title:&nbsp;Impact of Cilostazol on Angiographic Restenosis after Balloon Angioplasty for Infrapopliteal Artery Disease in Patients with Critical Limb Ischemia&nbsp;Reference:&nbsp;Y. Soga et al. European Journal of Vascular and Endovascular Surgery 44 (2012) 577e581. Angioplasty is regularly used for patients with critical limb ischemia where restenosis is a great limitation, especially in infrapopliteal territory.&nbsp; The use<a href="https://solaci.org/en/2012/11/30/cilostazol-reduces-restenosis-in-infrapopliteal-angioplasty/" title="Read more" >...</a>

Top